FlexAbility Ablation Catheter
Device
Abbott Laboratories
Total Payments
$1.8M
Transactions
919
Doctors
400
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $608,453 | 110 | 32 |
| 2020 | $1.0M | 205 | 39 |
| 2019 | $53,835 | 232 | 119 |
| 2018 | $151,331 | 372 | 259 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.6M | 233 | 89.4% |
| Consulting Fee | $156,558 | 128 | 8.6% |
| Food and Beverage | $28,061 | 526 | 1.5% |
| Travel and Lodging | $4,505 | 19 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $1,800 | 1 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $1,700 | 3 | 0.1% |
| Education | $612.28 | 9 | 0.0% |
Payments by Type
Research
$1.6M
233 transactions
General
$193,236
686 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of Ventricular Tachycardia (LESS-VT) Study | Abbott Laboratories | $981,508 | 0 |
| DECAAFII Study | Abbott Laboratories | $406,428 | 0 |
| FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of VT Study (LESS-VT) | Abbott Laboratories | $122,488 | 0 |
| LESS-VT | Abbott Laboratories | $54,843 | 0 |
| Characterization of lesions created by new design catheters in the canine heart | Abbott Laboratories | $36,000 | 0 |
| AF-Stop Aim 3 | Abbott Laboratories | $22,500 | 0 |
Top Doctors Receiving Payments for FlexAbility Ablation Catheter
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Baltimore, MD | $1.6M | 234 |
| , MD | Cardiovascular Disease | Atlanta, GA | $44,731 | 6 |
| , M.D | Cardiovascular Disease | New York, NY | $23,588 | 3 |
| , MD MPH | Clinical Cardiac Electrophysiology | New Orleans, LA | $17,320 | 18 |
| , MD | Cardiovascular Disease | Salt Lake City, UT | $15,000 | 23 |
| , MD | Cardiovascular Disease | New York, NY | $8,750 | 11 |
| , MD | Cardiovascular Disease | New York, NY | $8,750 | 11 |
| , M.D | Cardiovascular Disease | Cooperstown, NY | $8,750 | 11 |
| , M.D | Clinical Cardiac Electrophysiology | El Paso, TX | $7,950 | 13 |
| , M.D | Cardiovascular Disease | Minneapolis, MN | $7,744 | 15 |
| , D.O | Internal Medicine | Palos Park, IL | $3,645 | 2 |
| , MD | Cardiovascular Disease | Las Vegas, NV | $2,418 | 3 |
| , M.D | Internal Medicine | Port Charlotte, FL | $2,010 | 10 |
| , MD | Internal Medicine | Los Angeles, CA | $1,700 | 3 |
| , MD | Clinical Cardiac Electrophysiology | Charleston, WV | $1,382 | 10 |
| , M.D | Clinical Cardiac Electrophysiology | Fredericksburg, TX | $1,338 | 1 |
| , M.D | Clinical Cardiac Electrophysiology | Little Rock, AR | $1,248 | 1 |
| , M.D | Cardiovascular Disease | Towson, MD | $968.88 | 6 |
| , MD | Clinical Cardiac Electrophysiology | Towson, MD | $968.88 | 6 |
| , M.D | Internal Medicine | Los Angeles, CA | $750.00 | 1 |
| , M.D | Cardiovascular Disease | Cortlandt Manor, NY | $713.01 | 6 |
| , M.D | Cardiovascular Disease | Cortlandt Manor, NY | $713.01 | 6 |
| , MD | Internal Medicine | Baltimore, MD | $669.00 | 1 |
| , M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Thousand Oaks, CA | $650.00 | 1 |
| , M.D | Internal Medicine | Los Angeles, CA | $562.50 | 1 |
Ad
Manufacturing Companies
- Abbott Laboratories $1.8M
Product Information
- Type Device
- Total Payments $1.8M
- Total Doctors 400
- Transactions 919
About FlexAbility Ablation Catheter
FlexAbility Ablation Catheter is a device associated with $1.8M in payments to 400 healthcare providers, recorded across 919 transactions in the CMS Open Payments database. The primary manufacturer is Abbott Laboratories.
Payment data is available from 2018 to 2021. In 2021, $608,453 was paid across 110 transactions to 32 doctors.
The most common payment nature for FlexAbility Ablation Catheter is "Unspecified" ($1.6M, 89.4% of total).
FlexAbility Ablation Catheter is associated with 6 research studies, including "FLExAbility Sensor Enabled Substrate Targeted Ablation for the Reduction of Ventricular Tachycardia (LESS-VT) Study" ($981,508).